VEGFA and neoplasm: Treatment with bevacizumab, a humanized monoclonal antibody that specifically neutralizes VEGF-A, has been documented to lead to hearing improvement or tumor shrinkage in 30–60% of NF2 patients and is approved for NF2 treatment in the United Kingdom [18].